BeiGene lung cancer treatment meets main goal in late-stage study

[January 21, 2020]  (Reuters) - BeiGene Ltd said on Tuesday its cancer therapy combination for treating lung cancer in previously untreated patients met the main goal in a late-stage study.

The therapy, tislelizumab, when administered in combination with chemotherapy helped reduce the risk of cancer progression in patients with squamous non-small cell lung cancer.

(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shounak Dasgupta)

[© 2020 Thomson Reuters. All rights reserved.]

Copyright 2020 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.